anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to investigate the efficacy of occupational therapy for patients with upper limb disabilities, specifically utilizing the ALBA® device for training. Robotic equipment has been introduced as part of rehabilitation techniques for the upper extremity with promising results, and the ALBA® device is being used in this project to assess its effectiveness. A randomized controlled trial will be conducted, comparing a control group receiving conventional treatment and an experimental group receiving a combination of conventional treatment and ALBA® training. Participants will be adults with hemiparesis secondary to an acquired brain lesion, selected from a convenience sample of inpatients at Los Coihues clinic after concealing the inclusion and exclusion criteria.

All participants will perform 45 minutes of training, 5 days a week, for 4 weeks, totaling 20 sessions. The control group will receive 45 minutes of conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. The experimental group will receive 20 minutes of conventional treatment associated with 25 minutes of supervised ALBA® training. The ALBA® training will involve customizing the device software to the patient's progress and adjusting the angles of inclination for exercises. Each session will feature a virtual assistant guiding patients through a sequence of exercises, including a brief practice period, two series of repetitions of different movements, and a free exercise. Rest periods of 2-3 minutes will be given between each series. Assessments will be taken before training (t1), at 4 weeks (t2), and at 3 months (t3) to evaluate the effectiveness of the two treatment methods. This study design allows for the evaluation of both short and long-term effects. Overall, this study aims to provide evidence for the effectiveness of the ALBA® device for the rehabilitation of upper extremities and contribute to the existing literature on the use of robotic equipment in occupational therapy.
PURPOSE: To obtain a dyeing agent for human hair dyeing that comprises isatin or its derivative and aminoindole or aminoindoline dye, and is stable to sunlight, bad weather and chemicals. CONSTITUTION: This keratin fiber dyeing agent comprises (A) a composition containing a compound of formula I (R1 is H, or an alkyl, acetyl, etc.; R2 and R3 are each H, an alkyl, OH, a amino, phenyl, etc.), (preferably isantin), and (B) an medium composition containing aminoindole or its salt of formula II (R4 and R6 are each H, an alkyl; R5 is H, an alkyl, etc.; Z, is H, an alkyl, etc.; Z2 is H, an alkyl) or aminoindoline or its salt of formula III (R7 and R8 are each H or an alkyl; X2 is H or NH2 ; R9 is H, an alkyl, etc.). To dye human hair with this dyeing agent, components A and B may be mixed immediately before dyeing hair, or component A may be applied to hair before or after component B is applied to hair at an interval of time of 5-40min between applications of both components of the dyeing agent.
Apply a thin film of fluticasone propionate lotion to the affected skin areas once daily. Rub in gently. 

Discontinue use when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. 

The safety and efficacy of fluticasone propionate lotion have not been established beyond 4 weeks of use. 

Avoid use with occlusive dressings or application to the diaper area [see Warnings and Precautions (Error! Hyperlink reference not valid.) and (Error! Hyperlink reference not valid.)].

Fluticasone propionate lotion is for topical use only, and not for ophthalmic, oral, or intravaginal use.
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The investigators will perform 24-hour ambulatory blood pressure monitoring (ABPM) and ambulatory skin sympathetic nerve activity (SKNA) recording using a Bittium Faros electrocardiogram (ECG) monitor, assess the number of syncope and presyncope episodes and determine the symptoms using validated questionnaires at baseline. The patients will then be given mirabegron (either 25 mg once daily or 50 mg once daily) for eight weeks. Afterward, the patient will return to the clinic for clinical assessments, complete questionnaires, ABPM, and ambulatory SKNA recording while still on treatment. Mirabegron will be stopped when the data collection is complete. Because mirabegron has a long half-life, the investigators will schedule a video visit with the patient 12 weeks after beginning the treatment and inquire about the patient's symptoms. The investigators will repeat all pertinent questionnaires at that time.
Risk Summary

There are no available data on DEFITELIO use in pregnant women. When administered to pregnant rabbits during the period of organogenesis at doses that were comparable to the recommended human dose based on body surface area, defibrotide sodium decreased the number of implantations and viable fetuses. Advise pregnant women of the potential risk of miscarriage.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Data

Animal Data

Embryo-Fetal toxicity assessment was attempted in rats and rabbits, but was not possible because of high maternal mortality, abortion, and fetal resorption at all doses. Pregnant rats were administered defibrotide sodium from gestational day (GD) 6 to 15 at 0, 240, 1200, and 4800 mg/kg/day by continuous intravenous infusion over 24 hours or at 60, 120, and 240 mg/kg/day by 2-hour infusions 4 times per day. Pregnant rabbits were administered defibrotide sodium at 0, 30, 60, or 120 mg/kg/day from GD 6 to 18 by 2-hour infusions 4 times per day.

In another study in pregnant rabbits, 3 separate subgroups of animals were treated with doses of 80 mg/kg/day defibrotide sodium administered by 2-hour infusions 4 times per day for 5 days each in a staggered manner during the organogenesis period. The dose of 80 mg/kg/day is approximately equivalent to the recommended clinical dose on a mg/m2 basis. Subgroup 1 was dosed from GD 6 to 10, subgroup 2 was dosed from GD 10 to 14, and subgroup 3 was dosed from GD 14 to 18. An increased incidence of unilateral implantation was observed in defibrotide sodium-treated animals. Treatment with defibrotide sodium resulted in a decreased number of implantations and viable fetuses.
The invention relates to a chymotrypsin preparation, particularly relates to chymotrypsin composition freeze-dried powder and a preparation method thereof. The hymotrypsin composition freeze-dried powder comprises chymotrypsin, dextran 20 and sorbitol, wherein the ratio of chymotrypsin to dextran 20 to sorbitol is 1 million units: 1-1.8g: 0.05-0.6g. The average porosity of the hymotrypsin composition freeze-dried powder is 85-98%. The invention further relates to a preparation method of the hymotrypsin composition freeze-dried powder. The hymotrypsin composition freeze-dried powder disclosed herein has the advantages of full and uniform appearance, high porosity, good re-solubility, high stability, simple prescription, low proportion of pharmaceutic adjuvants, low side effect to human body, safety and reliability. According to the invention, the preparation technology of the hymotrypsin composition freeze-dried powder is further improved, the temperature, liquid volume, and freeze-drying process are improved, and sterilization is conducted twice.
PURPOSE:A specific DNA fragment is introduced into the cloning site in the downstream of the promotor gene in the expression vector and the resultant vector is introduced into the host to enable high-efficiency production of a protein like human apolipoprotein. CONSTITUTION:A DNA fragment containing DNA coding for apolipoprotein or a substance having a similar physiological activity to human apolipoprotein is prepared. The resultant DNA fragment is introduced into the expression vector at the cloning site in the downstream of the promotor gene. Then, the vector including the DNA fragment is introduced into the host, the host is cultured to collect the protein produced. Some of the promotors are controllable by 1acI. The resultant protein is used as an antigen to produce an antiserum according to usual manner and the antiserum is used to detect apolipoprotein A-1.
<P>PROBLEM TO BE SOLVED: To provide a pancreatic lipase inhibitor which is active owing to a pancreatic lipase activity-inhibitory effect of the extract of Xiangru as a crude drug, particularly that of Mosla chinensis Maxim. or Elsholtzia ciliata Hylander, Elsholtzia splendens Nakai ex F. Maekawa, based on the study of their pharmacological activity, and to provide a composition preventing lipid accumulation, such as having anti-obese, lipid absorption-inhibitory and blood neutral lipid level-inhibitory effects, owing to the above inhibitor.  <P>SOLUTION: The pancreatic lipase inhibitor is characterized by comprising the solvent extract of Xiangru as the active ingredient. The composition containing the inhibitor is also provided, preventing lipid accumulation, such as having anti-obese, lipid absorption-inhibitory and blood neutral lipid level-inhibitory effects, owing to the above inhibitor. In this composition, the Xiangru to undergo extraction is Mosla chinensis Maxim. or Elsholtzia ciliata Hylander, Elsholtzia splendens Nakai ex F. Maekawa, the extractive solvent is water. This composition is in the form of food, especially a kind of specific health food, or a pharmaceutical or the like.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Obstructive sleep apnea (OSA) as an indication for adenotonsillectomy has increased significantly over the past ten years, and now has surpassed recurrent tonsillitis as the most common indication for this procedure. Opioids continue to be the most commonly administered pain medication for these procedures. Studies have shown that patients with OSA have significantly increased sensitivity to opioids that results in post-operative respiratory depression and apnea when administered via standard opioid dosing protocols. Children with OSA were shown to have a nearly fivefold increase in the odds of developing respiratory complications when compared to their counterparts with tonsillitis. Ketorolac possesses similar efficacy to morphine without the problematic complications of respiratory depression, nausea and vomiting, which are commonly seen post-adenotonsillectomy. Importantly, when combined with opioids, ketorolac is opioid-sparing. This synergistic effect means that a similar level of analgesia is achieved using a lower dose of opioid. However, there continues to be concern about using ketorolac due to the potential risk of post-operative bleeding from anti-platelet activity.

This randomized, prospective study aims to determine the effect of ketorolac on the total dose of morphine required to achieve postoperative analgesia in children with OSA undergoing adenotonsillectomy. Participants will be randomly assigned to receive ketorolac or to not receive ketorolac. The post-anesthesia care unit (PACU) nurses, who will be blinded to ketorolac administration, will evaluate the patients using the Face, Legs, Activity, Cry, Consolability (FLACC) scale scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. For patients with a FLACC score of 6-10, morphine (0.05mg/kg) will be administered. For patients with FLACC scores of 3-5, morphine (0.025mg/kg) will be administered. The total amount of opioid required to obtain a FLACC score of less than 3 will be evaluated as the primary outcome. The secondary outcomes to be evaluated will be PACU FLACC scores, time required in PACU, incidence of post-tonsillectomy bleeding and total pain medications administered during hospital admission.
Premature ovarian insufficiency (POI) has no curative treatment until now. Filgrastim is an FDA approved Granulocyte-Colony Stimulating factor (G-CSF). Very small embryonic-like stem cells (VSELs) are found in the testis and ovary. VSELs are stem cells that have noticed to survive chemotherapy induced gonadal failure. Data from animal studies showed that stimulation of these stem cells result in generation of the affected gonads. Studies on mice have shown a promising stimulating effect of Filgrastim on recovery of spermatogenesis and oogenesis after chemotherapy-induced gonadal failure (in 2013, 2014, and 2015).
Sitagliptin, a DPP-4 inhibitor was used as an incretin enhancer in clinical practice first. In clinical trials, sitagliptin showed effective control of blood glucose level in type 2 diabetes and 100 mg once daily with metformin was similar to sulfonylurea (glipizide) with metformin in lowering HbA1c. Mostly in practice, stable blood glucose levels were maintained after change of sulfonylurea to sitagliptin in type 2 diabetes treatment. However, in some cases, there were abrupt severe hyperglycemia and uncontrolled blood glucose level after drug change to sitagliptin.

Several mechanism could be considered for reduced response to DPP-4 inhibitor in some type 2 diabetes patients. Firstly, significantly reduced secretion of glucagon-like peptide 1 (GLP-1) more than expected in diabetes or functional defect of GLP-1 activity could be the mechanism of loss of GLP-1 effect irrespective of DPP-4. Secondly, mutation or functional defect of DPP-4 enzyme could not be inhibited by DPP-4 inhibitor. Thirdly, GLP-1 receptor mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to DPP-4 inhibitor.
The investigators will conduct a study in Veterans and non-Veterans with diagnosed PD to compare PDAE versus walking for OFF-time, cognition, and brain cell protection. The investigators will use a method like a coin flip to decide if the participants will be doing PDAE or walking. Importantly, the investigators will see if brain cells are protected using a brain scan that looks at the areas affected by PD to determine the relative amounts of different hormones in the brain that are related to having Parkinson's. The investigators will use these measurements of these hormones to chart the course of brain cell breakdown in patients with PD who have done walking or PDAE for 16 months. The investigators think that that PDAE will be better at lessening OFF-time and making cognition better than walking. The investigators think this because participants have to really use the mind during PDAE because the participants have so much to think about in terms of the steps and patterns. The investigators will assign 102 Veterans with mild-moderate PD to either 16 months of PDAE or walking. The investigators will use a coin toss or other similar method to determine who goes in what group. The investigators need participants to be in the classes for 16-months because it takes that long for us to see if anything changed in the brain with those hormones. Participants will do twice weekly classes for the first 3 months and then will switch down to taking lessons just 1 time per week for 13 months. The investigators will schedule appointments for participants to be seen by the research team before Veterans begin lessons, at 3 months (after the twice weekly schedule) and at 16 months after all the lessons are completed. The appointments will consist of asking the Veterans about their OFF-time having them take a few memory and thinking tests. The investigators will also ask them to lie in a scanner for about an hour. The participants can rest in the scanner for about a 1/2 hour and also do a thinking task. The investigators will be able to answer the questions, "Is PDAE better than walking at lessening OFF-time and spatial cognition and slowing down brain cell death? This study is using cutting edge imaging techniques for the first time to see if dance or walking are helpful for slowing brain cell death. This project combines patient-centered, clinical science and mechanistic aims to improve health care.
One in-person exercise session with an exercise professional/weekly. A total of 20 hours of in-person coaching during the 20 weeks of intervention.
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
BACKGROUND: Respiratory failure can be a severe complication after polytrauma. Extensive systemic inflammation due to surgical interventions, as well as exacerbated post-traumatic immune responses influence the occurrence and progression of respiratory failure. This study investigated the effect of different surgical treatment modalities as well as combined inhibition of the complement component C5 and the toll-like receptor molecule CD14 (C5/CD14 inhibition) on the pulmonary microRNA (miRNA) signature after polytrauma, using a translational porcine polytrauma model.
METHODS: After induction of general anesthesia, animals were subjected to polytrauma, consisting of blunt chest trauma, bilateral femur fractures, hemorrhagic shock, and liver laceration. One sham group (n=6) and three treatment groups were defined; Early Total Care (ETC, n=8), Damage Control Orthopedics (DCO, n=8), and ETC + C5/CD14 inhibition (n=4). Animals were medically and operatively stabilized, and treated in an ICU setting for 72 h. Lung tissue was sampled, miRNAs were isolated, transcribed, and pooled for qPCR array analyses, followed by validation in the individual animal population. Lastly, mRNA target prediction was performed followed by functional enrichment analyses.
RESULTS: The miRNA arrays identified six significantly deregulated miRNAs in lung tissue. In the DCO group, miR-129, miR-192, miR-194, miR-382, and miR-503 were significantly upregulated compared to the ETC group. The miRNA expression profiles in the ETC + C5/CD14 inhibition group approximated those of the DCO group. Bioinformatic analysis revealed mRNA targets and signaling pathways related to alveolar edema, pulmonary fibrosis, inflammation response, and leukocytes recruitment. Collectively, the DCO group, as well as the ETC + C5/CD14 inhibition group, revealed more anti-inflammatory and regenerative miRNA expression profiles.
CONCLUSION: This study showed that reduced surgical invasiveness and combining ETC with C5/CD14 inhibition can contribute to the reduction of pulmonary complications.
The present invention provides a bacteriocin which can be easily produced in large amounts, has high antibacterial activity even at low concentrations, has a broad antibacterial spectrum, and has a low possibility of producing resistant bacteria. The bacteriocin is characterized by having an amino acid sequence which brings about antibacterial activity by deletion, substitution, insertion and/or addition of 1 or several amino acids in the amino acid sequence represented by SEQ ID No. 1 or SEQ ID No. 2 of the sequence Listing, or the amino acid sequence represented by SEQ ID No. 1 or SEQ ID No. 2 of the sequence Listing, and by having an isoelectric point of 12 or more.
PURPOSE:The titled preparation that contains, as an active ingredient, polysaccharides isolated from ginseng. CONSTITUTION:Polysaccharides, preferably containing at least one monosaccharide selected from arabinose, galactose, and glucose and having more than 100,000mol.wt., which have been isolated from ginseng, are used to give the objective preparation stimulating biological defensive ability such as functional stimulation of reticuloendothelial system, resistance to microbism and antitumor ability. The preparation is in the form of dust, granules, tablets, capsules, syrup or injection solution and is given orally or parenterally. The dose is 0.1-1,000 mg/day/man based on the polysaccharide in oral administration once a day or in portions. The polysaccharide is extracted from genseng with water and the extract is precipitated by addition of an organic solvent. Then, the precipitate is subjected to chromatography with an ion-exchange resin or gel filtration agent.
Cardiac ischaemia/reperfusion (I/R) impairs mitochondrial function, resulting in excessive oxidative stress and cardiomyocyte ferroptosis and death. Nuclear factor E2-related factor 2 (Nrf2) is a key regulator of redox homeostasis and has cardioprotective effects against various stresses. Here, we tested whether CBR-470-1, a noncovalent Nrf2 activator, can protect against cardiomyocyte death caused by I/R stress. Compared with vehicle treatment, the administration of CBR-470-1 (2 mg/kg) to mice significantly increased Nrf2 protein levels and ameliorated the infarct size, the I/R-induced decrease in cardiac contractile performance, and the I/R-induced increases in cell apoptosis, ROS levels, and inflammation. Consistently, the beneficial effects of CBR-470-1 on cardiomyocytes were verified in a hypoxia/reoxygenation (H/R) model in vitro, but this cardioprotection was dramatically attenuated by the GPX4 inhibitor RSL3. Mechanistically, CBR-470-1 upregulated Nrf2 expression, which increased the expression levels of antioxidant enzymes (NQO1, SOD1, Prdx1, and Gclc) and antiferroptotic proteins (SLC7A11 and GPX4) and downregulated the protein expression of p53 and Nlrp3, leading to the inhibition of ROS production and inflammation and subsequent cardiomyocyte death (apoptosis, ferroptosis and pyroptosis). In summary, CBR-470-1 prevented I/R-mediated cardiac injury possibly through inhibiting cardiomyocyte apoptosis, ferroptosis and pyroptosis via Nrf2-mediated inhibition of p53 and Nlrp3 and activation of the SLC7A11/GPX4 pathway. Our data also highlight that CBR-470-1 may serve as a valuable agent for treating ischaemic heart disease.
The invention discloses a traditional Chinese medicine composition for auxiliary treatment for canine parvovirus disease and a preparing method thereof. The composition comprises a traditional Chinese medicine named as Chinese characters 'Longshencao' by the inventor, polygonum manshuriense and kochia scoparia f. trichophylla. The composition comprises 25-45 parts by weight of the traditional Chinese medicine named as Chinese characters 'Longshencao' by the inventor, 5-15 parts by weight of the polygonum manshuriense and 30-50 parts by weight of kochia scoparia f. trichophylla. The preparing method includes cleaning the 'Longshencao', the polygonum manshuriense and the kochia scoparia f. trichophylla, airing, mixing the 'Longshencao', the polygonum manshuriense and the kochia scoparia f. trichophylla, smashing, adding water, digesting at 40-50 DEG C for twice, combining leach liquors, concentrating, adding pharmaceutically acceptable auxiliary materials, and preparing into medicine preparations according to conventional preparation preparing methods in the field of medicines. The composition adopts natural traditional Chinese medicines as raw materials, is unique in compatibility of medicines and simple in preparing method, and has functions of clearing heat and toxins, reliving dysentery and arresting vomiting. The composition is advantaged by high absorptivity, a high utilization rate, safety, no side or toxic effects, high stability, durable medicine effects, wide raw material sources and a low cost, and has a good application prospect in the field of preventing and treating the canine parvovirus disease.